Codex_V5

Marousek GI

References:

Rank: 2 - Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens.(Nov 2007)
Rank: 2 - Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant.(Jan 2008)
Rank: 2 - Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir.(Jul 2004)
Rank: 3 - Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients.(Feb 2007)
Rank: 3 - Cytomegalovirus UL97 kinase mutations that confer maribavir resistance.(Jul 2007)

Mutations:

Mutant	Gene	Virus	Reference
R233S	UL27	Human betaherpesvirus 5	Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir. (Jul 2004)
W362R	UL27	Human betaherpesvirus 5	Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir. (Jul 2004)
D413A	UL54	Human betaherpesvirus 5	Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. (Feb 2007)
D413A	UL54	Human betaherpesvirus 5	Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. (Feb 2007)
D413A	UL54	Human betaherpesvirus 5	Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. (Feb 2007)
T813S	UL54	Human betaherpesvirus 5	Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. (Nov 2007)
T813S	UL54	Human betaherpesvirus 5	Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. (Nov 2007)
T813S	UL54	Human betaherpesvirus 5	Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. (Nov 2007)
G841A	UL54	Human betaherpesvirus 5	Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. (Nov 2007)
G841A	UL54	Human betaherpesvirus 5	Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. (Nov 2007)
G841A	UL54	Human betaherpesvirus 5	Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. (Nov 2007)
V353A	UL97	Human betaherpesvirus 5	Cytomegalovirus UL97 kinase mutations that confer maribavir resistance. (Jul 2007)
V353A	UL97	Human betaherpesvirus 5	Cytomegalovirus UL97 kinase mutations that confer maribavir resistance. (Jul 2007)
H411L	UL97	Human betaherpesvirus 5	Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant. (Jan 2008)
H411L	UL97	Human betaherpesvirus 5	Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant. (Jan 2008)
H411N	UL97	Human betaherpesvirus 5	Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant. (Jan 2008)
H411N	UL97	Human betaherpesvirus 5	Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant. (Jan 2008)
601-602del	UL97	Human betaherpesvirus 5	Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. (Feb 2007)
601-603del	UL97	Human betaherpesvirus 5	Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. (Feb 2007)

CHARMD

Comprehensive Herpesviruses Antiviral drug Resistance Mutation Database

Marousek GI

Mutations: